Physician profile
Brian C Hard
NPI 1225216864
$5,501.53
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,385 · 2020: $450 · 2021: $81.13 · 2022: $474 · 2023: $1,019 · 2024: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.59 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $431.14 | 2019-2024 | Briviact, Rystiggo |
| Novartis Pharmaceuticals Corporation | $353.77 | 2019-2023 | |
| Abbvie INC. | $340.43 | 2019-2024 | |
| Biogen, INC. | $337.57 | 2019-2024 | Tysabri, Vumerity, Avonex |
| Pfizer INC. | $312.70 | 2019-2024 | |
| Mdd US Operations, LLC | $258.05 | 2019-2024 | Gocovri |
| Alexion Pharmaceuticals, INC. | $229.16 | 2019-2024 | Ultomiris |
| Genentech USA, INC. | $189.44 | 2019-2024 | Ocrevus, Enspryng, Evrysdi |
| Teva Pharmaceuticals USA, INC. | $165.90 | 2019-2023 | Austedo, Austedo Xr |
| Greenwich Biosciences, INC. | $156.84 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $152.11 | 2019-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $149.85 | 2022 | |
| Genzyme Corporation | $137.19 | 2019 | |
| Allergan, INC. | $136.32 | 2019-2020 | |
| Celgene Corporation | $131.44 | 2022-2024 | Zeposia |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $126.33 | 2019-2023 | Aimovig |
| Ge Healthcare | $118.57 | 2019-2020 | |
| Lilly USA, LLC | $112.57 | 2019-2024 | Amyvid |
| Eisai INC. | $111.65 | 2019-2024 | |
| Lundbeck LLC | $109.21 | 2019-2024 | Vyepti |
| Upsher-Smith Laboratories LLC | $102.20 | 2019-2022 | |
| Livanova USA, INC. | $100.11 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Csl Behring | $94.06 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $83.63 | 2019-2024 | Nuplazid |
| Argenx US, INC. | $82.32 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $76.83 | 2019-2023 | Rytary |
| Merz North America, INC. | $73.01 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $67.01 | 2021 | |
| Sk Life Science, INC. | $63.50 | 2022-2024 | |
| Emd Serono, INC. | $63.37 | 2019-2020 | |
| Acorda Therapeutics, INC | $63.12 | 2019 | |
| Supernus Pharmaceuticals, INC. | $61.74 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $46.96 | 2019 | |
| Tersera Therapeutics LLC | $41.18 | 2019 | |
| Bausch Health US, LLC | $39.29 | 2019-2020 | |
| Neurelis, INC. | $35.56 | 2024 | Valtoco |
| Corium, LLC | $35.09 | 2022-2023 | Adlarity |
| Ipsen Biopharmaceuticals, INC | $34.77 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.04 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.93 | 2023 | Rexulti |
| Grifols USA, LLC | $28.82 | 2019 | |
| Sumitomo Pharma America, INC. | $28.42 | 2024 | Aptiom |
| Kyowa Kirin, INC. | $23.56 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $23.15 | 2019 | |
| Microtransponder, INC. | $22.35 | 2024 | |
| Medtronic, INC. | $18.64 | 2024 | Intellis Adaptivestim |
| Cala Health, INC. | $17.25 | 2023 | Cala Trio |
| Varian Medical Systems, INC. | $15.55 | 2020 | |
| Si-Bone, INC. | $13.89 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.52 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.